Capivasertib联合紫杉醇一线治疗转移性三阴性乳腺癌:PAKT试验
PAKT是一项双盲、安慰剂对照、随机II期试验,共纳入140例未经治疗的转移性三阴性乳腺癌患者,按1:1随机分配至紫杉醇联合capivasertib或安慰剂组。主要终点无进展生存期(PFS)在联合组为5.9个月 vs 4.2个月(HR 0.74;95%CI 0.50-1.08;HR 0.61;95%CI 0.37-0.99;在PIK3CA/AKT1/PTEN突变亚组(n=28)中,联合组PFS为9.3个月 vs 3.7个月(HR 0.30;95%CI 0.11-0.79;
要点
- Capivasertib联合紫杉醇一线治疗转移性TNBC显著延长OS(19.1 vs 12.6个月)。
- PIK3CA/AKT1/PTEN突变亚组获益更显著,PFS HR 0.30。
- 联合组常见≥3级不良事件为腹泻(13% vs 1%)、感染(4% vs 1%)等。
核心结论
- 在紫杉醇基础上加用AKT抑制剂capivasertib一线治疗转移性TNBC,显著延长PFS和OS,尤其在PIK3CA/AKT1/PTEN突变肿瘤中获益更明显。
研究设计与样本
- 双盲、安慰剂对照、随机II期试验(PAKT),共纳入140例未经治疗的转移性TNBC女性患者,按1:1随机分配。
- 治疗方案:紫杉醇90 mg/m2(第1、8、15天)联合capivasertib 400 mg每日两次或安慰剂(第2-5、9-12、16-19天),每28天为一周期,直至疾病进展或不可耐受毒性。
- 主要终点为PFS;次要终点包括OS、PIK3CA/AKT1/PTEN突变亚组的PFS和OS、肿瘤缓解及安全性。
关键数值与推荐
- 最常见≥3级不良事件(capivasertib联合组 vs 安慰剂联合组):腹泻13% vs 1%,感染4% vs 1%,中性粒细胞减少3% vs 3%,皮疹4% vs 0%,乏力4% vs 0%。
临床怎么用
- 对于转移性TNBC患者,一线紫杉醇联合capivasertib可能改善生存,尤其在PIK3CA/AKT1/PTEN突变肿瘤中。
- 治疗期间需密切监测腹泻、感染、皮疹等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been associated with activation of PI3K or AKT and/or deletions of PTEN. The PAKT trial was designed to evaluate the safety and efficacy of adding capivasertib to paclitaxel as first-line therapy for TNBC. PATIENTS AND METHODS: This double-blind, placebo-controlled, randomized phase II trial recruited women with untreated metastatic TNBC. A total of 140 patients were randomly assigned (1:1) to paclitaxel 90 mg/m2 (days 1, 8, 15) with either capivasertib (400 mg twice daily) or placebo (days 2-5, 9-12, 16-19) every 28 days until disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), PFS and OS in the subgroup with PIK3CA/AKT1/PTEN alterations, tumor response, and safety. RESULTS: Median PFS was 5.9 months with capivasertib plus paclitaxel and 4.2 months with placebo plus paclitaxel (hazard ratio [HR], 0.74; 95% CI, 0.50 to 1.08; 1-sided P = .06 [predefined significance level, 1-sided P = .10]). Median OS was 19.1 months with capivasertib plus paclitaxel and 12.6 months with placebo plus paclitaxel (HR, 0.61; 95% CI, 0.37 to 0.99; 2-sided P = .04). In patients with PIK3CA/AKT1/PTEN-altered tumors (n = 28), median PFS was 9.3 months with capivasertib plus paclitaxel and 3.7 months with placebo plus paclitaxel (HR, 0.30; 95% CI, 0.11 to 0.79; 2-sided P = .01). The most common grade ≥ 3 adverse events in those treated with capivasertib plus paclitaxel versus placebo plus paclitaxel, respectively, were diarrhea (13% v 1%), infection (4% v 1%), neutropenia (3% v 3%), rash (4% v 0%), and fatigue (4% v 0%). CONCLUSION: Addition of the AKT inhibitor capivasertib to first-line paclitaxel therapy for TNBC resulted in significantly longer PFS and OS. Benefits were more pronounced in patients with PIK3CA/AKT1/PTEN-altered tumors. Capivasertib warrants further investigation for treatment of TNBC.
引用
- Schmid P, Abraham J, Chan S, et al. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. J Clin Oncol. 2019. PMID: 31841354. doi:10.1200/JCO.19.00368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。